Abstract:Based on extensive experimental studies, a huge number of phytochemicals showed potential activity against tuberculosis (TB) at a lower minimum inhibitory concentration (MIC) and fewer toxicity profiles. However, these promising drugs have not been able to convert from ′lead′ to ′mainstream′ due to inadequate drug‐ability profiles. Thus, early drug‐prospective analyses are required at the primary stage to accelerate natural‐product‐based drug discovery with limited resources and time. In the present study, we have selected seventy‐three potential anti‐TB phytochemicals (MIC value ≤10 μg/mL) and assessed the drug‐ability profiles using bioinformatics and combinatorial chemistry tools, systematically. Primarily, the molecular docking study was done against two putative drug targets, catalase‐peroxidase enzyme (katG) and RNA polymerase subunit‐β (rpoB) of Mycobacterium tuberculosis (Mtb) using AutoDock 4.2 software. Further, assessed the drug‐ability score from Molsoft, toxicity profiles from ProTox, pharmacokinetics from SwisADME, hierarchical cluster analysis (HCA) by ChemMine tools and frontier molecular orbitals (FMOs) with Avogadro and structural activity relationships (SAR) analysis with ChemDraw 18.0 software. Above analyses indicated that, lower MIC exhibited anti‐TB phytochemicals, abietane, 12‐demethylmulticaulin exhibited poor docking and drug‐ability scores, while tiliacorinine, 2‐nortiliacorinine showed higher binding energy and drug‐ability profiles. Overall, tiliacorinine, 2‐nortiliacorinine, 7α‐acetoxy‐6β‐hydroxyroyleanone (AHR), (2S)‐naringenin and isovachhalcone were found as the most active and drug‐able anti‐TB candidates from 73 candidates. Phytochemicals are always a vital source of mainstream drugs, but the MIC value of a phytochemical is not sufficient for it to be promoted. An ideal drug‐ability profile is therefore essential for achieving clinical success, where advanced bioinformatics tools help to assess and analyse that profile. Additionally, several natural pharmacophores found in existing anti‐TB drugs in SAR analyses also provide crucial information for developing potential anti‐TB drug. As a conclusion, combined bioinformatics and combinatorial chemistry are the most effective strategies to locate potent‐cum‐drug‐able candidates in the current drug‐development module.

Exploring Anti-Tb Leads from Natural Products Library Originated from Marine Microbes and Medicinal Plants

Bioprospecting for Antituberculosis Leads from Microbial Metabolites

Marine natural products as potential anti-tubercular agents

The potential of marine natural Products: Recent Advances in the discovery of Anti-Tuberculosis agents

The past, present and future of tuberculosis treatment.

New Anti-Tuberculosis Drugs: Strategies, Sources and New Molecules

Anti-mycobacterial natural products and mechanisms of action

[Development of New Anti-Tuberculosis Drugs: the Strategy of Unconventional Microbial Culture and Silencing Gene Activation].

Natural products in anti-tuberculosis host-directed therapy

Antitubercular drugs: possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity

Recent developments in natural product-based drug discovery for tuberculosis

Drug-lead Anti-tuberculosis Phytochemicals: A Systematic Review

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

Genetics-directed Drug Discovery for Combating Mycobacterium Tuberculosis Infection

New anti-tuberculosis agents amongst known drugs

A Model to Predict Anti-Tuberculosis Activity: Value Proposition for Marine Microorganisms

Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors

Combined Bioinformatics and Combinatorial Chemistry Tools to Locate Drug‐Able Anti‐TB Phytochemicals: A Cost‐Effective Platform for Natural Product‐Based Drug Discovery

Recent Advances in Antitubercular Compounds Targeting Mycolic Acid Biosynthesis and Transport

Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases

A brief review on tuberculosis and recent findings in isolation of anti-tuberculosis compounds from endophytic fungi